Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era

There is a need for a more refined, molecularly based classification model for glioblastoma (GBM) in the temozolomide era.To refine the existing clinically based recursive partitioning analysis (RPA) model by incorporating molecular variables.NRG Oncology RTOG 0525 specimens (n = 452) were analyzed for protein biomarkers representing key pathways in GBM by a quantitative molecular microscopy-based approach with semiquantitative...